Carisma Therapeutics

Update in progress

CARM (OTC Markets OTCPK)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Carisma Therapeutics, Inc. is a biotechnology company developing therapies for liver fibrosis and cancer. Its pipeline includes CT-2401 in preclinical development for liver fibrosis and CT-1119, a mesothelin-targeted CAR-Monocyte in Phase 1 for advanced mesothelin-positive solid tumors. It also pursues in vivo CAR-M cell therapy for solid tumors and collaborates with ModernaTX on oncology gene therapies. Founded 2016 as CARMA Therapeutics; renamed Carisma in 2017. Based in Philadelphia, PA.

Company score

Sentiment: -0.37; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.16; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.21; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.00; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive